RT Journal Article
SR Electronic
T1 Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.12.23289860
DO 10.1101/2023.05.12.23289860
A1 Darst, Burcu F.
A1 Shen, Jiayi
A1 Madduri, Ravi K.
A1 Rodriguez, Alexis A.
A1 Xiao, Yukai
A1 Sheng, Xin
A1 Saunders, Edward J.
A1 Dadaev, Tokhir
A1 Brook, Mark N.
A1 Hoffmann, Thomas J.
A1 Muir, Kenneth
A1 Wan, Peggy
A1 Marchand, Loic Le
A1 Wilkens, Lynne
A1 Wang, Ying
A1 Schleutker, Johanna
A1 MacInnis, Robert J.
A1 Cybulski, Cezary
A1 Neal, David E.
A1 G. Nordestgaard, Børge
A1 Nielsen, Sune F.
A1 Batra, Jyotsna
A1 Clements, Judith A.
A1 Australian Prostate Cancer BioResource
A1 Grönberg, Henrik
A1 Pashayan, Nora
A1 Travis, Ruth C.
A1 Park, Jong Y.
A1 Albanes, Demetrius
A1 Weinstein, Stephanie
A1 Mucci, Lorelei A.
A1 Hunter, David J.
A1 Penney, Kathryn L.
A1 Tangen, Catherine M.
A1 Hamilton, Robert J.
A1 Parent, Marie-Élise
A1 Stanford, Janet L.
A1 Koutros, Stella
A1 Wolk, Alicja
A1 Sørensen, Karina D.
A1 Blot, William J.
A1 Yeboah, Edward D.
A1 Mensah, James E.
A1 Lu, Yong-Jie
A1 Schaid, Daniel J.
A1 Thibodeau, Stephen N.
A1 West, Catharine M.
A1 Maier, Christiane
A1 Kibel, Adam S.
A1 Cancel-Tassin, Géraldine
A1 Menegaux, Florence
A1 John, Esther M.
A1 Grindedal, Eli Marie
A1 Khaw, Kay-Tee
A1 Ingles, Sue A.
A1 Vega, Ana
A1 Rosenstein, Barry S.
A1 Teixeira, Manuel R.
A1 NC-LA PCaP Investigators
A1 Kogevinas, Manolis
A1 Cannon-Albright, Lisa
A1 Huff, Chad
A1 Multigner, Luc
A1 Kaneva, Radka
A1 Leach, Robin J.
A1 Brenner, Hermann
A1 Hsing, Ann W.
A1 Kittles, Rick A.
A1 Murphy, Adam B.
A1 Logothetis, Christopher J.
A1 Neuhausen, Susan L.
A1 Isaacs, William B.
A1 Nemesure, Barbara
A1 Hennis, Anselm J.
A1 Carpten, John
A1 Pandha, Hardev
A1 De Ruyck, Kim
A1 Xu, Jianfeng
A1 Razack, Azad
A1 Teo, Soo-Hwang
A1 Canary PASS Investigators
A1 Newcomb, Lisa F.
A1 Fowke, Jay H.
A1 Neslund-Dudas, Christine
A1 Rybicki, Benjamin A.
A1 Gamulin, Marija
A1 Usmani, Nawaid
A1 Claessens, Frank
A1 Gago-Dominguez, Manuela
A1 Castelao, Jose Esteban
A1 Townsend, Paul A.
A1 Crawford, Dana C.
A1 Petrovics, Gyorgy
A1 Casey, Graham
A1 Roobol, Monique J.
A1 Hu, Jennifer F.
A1 Berndt, Sonja I.
A1 Van Den Eeden, Stephen K.
A1 Easton, Douglas F.
A1 Chanock, Stephen J.
A1 Cook, Michael B.
A1 Wiklund, Fredrik
A1 Witte, John S.
A1 Eeles, Rosalind A.
A1 Kote-Jarai, Zsofia
A1 Watya, Stephen
A1 Gaziano, John M.
A1 Justice, Amy C.
A1 Conti, David V.
A1 Haiman, Christopher A.
YR 2023
UL http://medrxiv.org/content/early/2023/05/15/2023.05.12.23289860.abstract
AB Genome-wide polygenic risk scores (GW-PRS) have been reported to have better predictive ability than PRS based on genome-wide significance thresholds across numerous traits. We compared the predictive ability of several GW-PRS approaches to a recently developed PRS of 269 established prostate cancer risk variants from multi-ancestry GWAS and fine-mapping studies (PRS269). GW-PRS models were trained using a large and diverse prostate cancer GWAS of 107,247 cases and 127,006 controls used to develop the multi-ancestry PRS269. Resulting models were independently tested in 1,586 cases and 1,047 controls of African ancestry from the California/Uganda Study and 8,046 cases and 191,825 controls of European ancestry from the UK Biobank and further validated in 13,643 cases and 210,214 controls of European ancestry and 6,353 cases and 53,362 controls of African ancestry from the Million Veteran Program. In the testing data, the best performing GW-PRS approach had AUCs of 0.656 (95% CI=0.635-0.677) in African and 0.844 (95% CI=0.840-0.848) in European ancestry men and corresponding prostate cancer OR of 1.83 (95% CI=1.67-2.00) and 2.19 (95% CI=2.14-2.25), respectively, for each SD unit increase in the GW-PRS. However, compared to the GW-PRS, in African and European ancestry men, the PRS269 had larger or similar AUCs (AUC=0.679, 95% CI=0.659-0.700 and AUC=0.845, 95% CI=0.841-0.849, respectively) and comparable prostate cancer OR (OR=2.05, 95% CI=1.87-2.26 and OR=2.21, 95% CI=2.16-2.26, respectively). Findings were similar in the validation data. This investigation suggests that current GW-PRS approaches may not improve the ability to predict prostate cancer risk compared to the multi-ancestry PRS269 constructed with fine-mapping.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Cancer Institute at the National Institutes of Health grant (grant numbers U19 CA214253 to C.A.H., R01 CA257328 to C.A.H., U19 CA148537 to C.A.H., R01 CA165862 to C.A.H., and R00 CA246063 to B.F.D.), the Prostate Cancer Foundation (grants 21YOUN11 to B.F.D. and 20CHAS03 to C.A.H.), an award from the Andy Hill Cancer Research Endowment Distinguished Researchers Program (B.F.D.), a Fred Hutch/University of Washington SPORE Career Enhancement Program award (BFD), and the Million Veteran Program-MVP017.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from all participants, and study protocols were approved by the Institutional Review Boards at each institute.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe summary statistics used in this investigation are available through dbGaP under accession code phs001120. 1000 Genomes Project data can be found online: https://www.internationalgenome.org/. UK Biobank data is available to researchers with approved applications.